Review
Biochemistry & Molecular Biology
Elena E. Vaiman, Natalia A. Shnayder, Maxim A. Novitsky, Vera S. Dobrodeeva, Polina S. Goncharova, Elena N. Bochanova, Margarita R. Sapronova, Tatiana E. Popova, Alexey A. Tappakhov, Regina F. Nasyrova
Summary: This review examines candidate genes encoding dopamine receptors as genetic predictors of AP-induced parkinsonism and AP-induced tardive dyskinesia in schizophrenia patients. While some positive associations were found, there is currently no definitive conclusion on the leading role of any specific SNVs/polymorphisms in the development of AIP and AITD.
Review
Psychiatry
Guy Chouinard, Fiammetta Cosci, Virginie-Anne Chouinard, Larry Alphs
Summary: This article introduces the ESRS and ESRS-A as valid tools for measuring drug-induced movement disorders, highlighting their value in clinical research and clinics.
PSYCHOTHERAPY AND PSYCHOSOMATICS
(2023)
Review
Behavioral Sciences
Lasse Brandt, Christiane Montag, Felix Bermpohl, Anna Finck, Esma Wieacker, Andreas Heinz, Stefan Gutwinski
Summary: Analysis of five studies indicates that in animal models, discontinuation of clozapine and olanzapine did not lead to an increase in vacuous chewing movements while higher dosages of risperidone discontinuation did. More research is needed to determine the differences between antipsychotics and their implications for clinical practice in humans.
BEHAVIOURAL BRAIN RESEARCH
(2022)
Article
Pharmacology & Pharmacy
Fernando Facal, Begona Portela, Almudena Gil-Rodriguez, Francisco Barros, Olalla Maronas, Angel Carracedo
Summary: CYP2D6 analysis is required before prescribing pimozide to detect poor metabolizers and prevent adverse drug reactions. This study presents a case of a schizophrenia spectrum disorder patient who experienced severe side effects due to pimozide prescription. Genetic analysis revealed the patient's poor metabolizer status for CYP2D6, highlighting the importance of pharmacogenetic guidelines and training for psychiatry specialists when prescribing antipsychotic drugs.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Pharmacology & Pharmacy
Rohit Singh, Sankha Shubhra Chakrabarti, Upinder Kaur
Summary: The study highlights the atypical manifestation of antipsychotic-associated Rabbit syndrome in the presence of a serotonergic antidepressant. The syndrome is characterized by vertical rhythmic movements of the perioral region, has a late onset, and typically spares the tongue.
DARU-JOURNAL OF PHARMACEUTICAL SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Roberto De Masi, Stefania Orlando, Vincenzo Toni, Maria Carmela Costa
Summary: We report a singular case of a 31-year-old woman who developed acute extrapyramidal syndrome and stable memory loss due to the incorrect use of Fluphenazine. MRI post-analysis showed a 6.5% loss in brain volume, indicating neurotoxic effects on cortical and sub-cortical grey matter.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Medicine, General & Internal
Giammarco Cascino, Rossella Ceres, Alessio Maria Monteleone, Paola Bucci, Giulia Maria Giordano, Silvana Galderisi, Palmiero Monteleone
Summary: This study aimed to investigate the switching of antipsychotic medications in people with schizophrenia and analyze potential predictors. Over a four-year period, 34.9% of the participants switched their medication. The use of first-generation antipsychotics and the presence of extrapyramidal symptoms at baseline were associated with switching antipsychotic classes.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Psychiatry
Tevfik Kalelioglu, Nesrin Karamustafalioglu, Murat Emul, Guler Celikel, Ipek Ozonder, Aysu Kara, Cenk Kilic, Suat Yalcin, Ecem Celik, Ugur Kilic, Ahoora Ladoni, Emma Ragone, Caroline Centeno, J. Kim Penberthy
Summary: A study found that antipsychotic medication can cause extrapyramidal syndromes (EPS), which are common side effects that may lead to discontinuation of treatment. Although some clinical features of specific EPSs are known, no specific laboratory parameter has been identified to predict the risk of developing EPS.
JOURNAL OF PSYCHIATRIC RESEARCH
(2023)
Review
Biochemistry & Molecular Biology
Francesco Cavallieri, Valentina Fioravanti, Francesco Bove, Eleonora Del Prete, Sara Meoni, Sara Grisanti, Marialuisa Zedde, Rosario Pascarella, Elena Moro, Franco Valzania
Summary: This review summarizes the clinical, biological, and neuroimaging features of COVID-19-related parkinsonism and discusses the possible pathophysiological mechanisms. The appearance of parkinsonism during or immediately after COVID-19 infection is a very rare event. Different mechanisms, including vascular damage and neuroinflammation, may play a role, and further long-term observational studies are needed to evaluate the association between COVID-19 infection and the development of Parkinson's Disease.
Review
Biochemistry & Molecular Biology
Elena E. Vaiman, Natalia A. Shnayder, Aiperi K. Khasanova, Anna Strelnik, Arseny J. Gayduk, Mustafa Al-Zamil, Margarita R. Sapronova, Natalia G. Zhukova, Daria A. Smirnova, Regina F. Nasyrova
Summary: Drug-induced parkinsonism (DIP) is a common neurologic adverse reaction in patients with schizophrenia treated with antipsychotics. It is caused by drugs that affect dopamine receptors and disrupt the signaling pathways of various neurotransmitter systems. The mechanisms of DIP development are still poorly understood despite existing theories.
Article
Behavioral Sciences
Jivago Ropke, Talita H. Ferreira-Vieira, Lia P. Iglesias, Laila Asth, Fabiola M. Ribeiro, Fabricio A. Moreira
Summary: The study demonstrated that increasing endocannabinoid levels can protect rats against haloperidol-induced TD through CB1 receptor mediation. High-VCM rats showed increased CB1 receptor expression, which was positively correlated with the number of VCMs.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
(2021)
Review
Neurosciences
Stuart J. McCarter, Rodolfo Savica
Summary: Levodopa-induced dyskinesia (LID) is a common complication of Parkinson's disease (PD), but occurs less frequently in atypical parkinsonism. The globus pallidus internus (GPi) may play a major role in the development and treatment of LID, but other cortical areas could also be involved. Atypical parkinsonism serves as a natural model for studying more effective therapies for LID.
JOURNAL OF PARKINSONS DISEASE
(2022)
Article
Psychology, Developmental
Hua Chen, Ning Lyu, Wenyaw Chan, Austin De La Cruz, Chadi Calarge
Summary: This study examines the utilization and predictors of adjuvant metformin among pediatric recipients of second-generation antipsychotics. The findings suggest that the utilization of adjuvant metformin is uncommon among pediatric SGA recipients, and early introduction of the medication among nonobese children is rare.
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY
(2023)
Article
Psychology, Clinical
Chittaranjan Andrade
Summary: Studies have shown that exposure to antipsychotic drugs during pregnancy, particularly in the first trimester, is not significantly associated with an increased risk of major congenital malformations (MCMs). However, exploratory analyses suggest that olanzapine may be linked to an increased risk of musculoskeletal malformations.
JOURNAL OF CLINICAL PSYCHIATRY
(2021)
Review
Clinical Neurology
Davide Martino, Vikram Karnik, Roongroj A. Bhidayasiri, Deborah A. A. Hall, Robert A. Hauser, Antonella M. Macerollo, Tamara M. Pringsheim, Daniel A. Truong, Stewart A. Factor, Matej Skorvanek, Anette Schrag, IPMDS Rating Scales Review Comm
Summary: An International Parkinson and Movement Disorder Society subcommittee aimed to rate the psychometric quality of severity and screening instruments for antipsychotic-associated movement disorders. They identified 23 instruments, of which 7 severity rating instruments and 3 screening instruments were recommended with caveats due to insufficient psychometric properties and long duration of administration. New psychometric studies and revision of existing instruments are recommended to address these caveats and improve the clarity of their nomenclature.
MOVEMENT DISORDERS
(2023)
Article
Psychiatry
Mikkel Hojlund, Henrik Stovring, Kjeld Andersen, Christoph U. Correll, Jesper Hallas
Summary: The study investigated the association between low-dose off-label quetiapine and changes in metabolic parameters. The results showed that low-dose quetiapine was associated with increased triglycerides and decreased high-density lipoprotein in all subjects, as well as increased HbA1c, total cholesterol, and low-density lipoprotein among those with normal baseline values.
ACTA PSYCHIATRICA SCANDINAVICA
(2023)
Review
Biochemistry & Molecular Biology
Marco Solmi, Giovanni Croatto, Giada Piva, Stella Rosson, Paolo Fusar-Poli, Jose M. Rubio, Andre F. Carvalho, Eduard Vieta, Celso Arango, Nicole R. DeTore, Elizabeth S. Eberlin, Kim T. Mueser, Christoph U. Correll
Summary: Psychosocial interventions play an important role in schizophrenia and early psychosis. However, the literature on this topic is heterogeneous and contradictory. This umbrella review summarizes the findings from multiple meta-analyses comparing the effectiveness of different psychosocial interventions with standard treatment or other active interventions. The results suggest that early intervention services and cognitive behavioral therapy have significant effects on symptom reduction and functional improvement in early psychosis. For schizophrenia patients, cognitive behavioral therapy, psychoeducation, and any family interventions show positive effects on symptom reduction, relapse prevention, and functional improvement.
MOLECULAR PSYCHIATRY
(2023)
Review
Biochemistry & Molecular Biology
Giovanni Croatto, Davy Vancampfort, Alessandro Miola, Miriam Olivola, Jess G. Fiedorowicz, Joseph Firth, Ovidiu Alexinschi, Marcel A. Gaina, Vladimir Makkai, Fernanda Cunha Soares, Leandro Cavaliere, Giorgia Vianello, Brendon Stubbs, Paolo Fusar-Poli, Andre F. Carvalho, Eduard Vieta, Samuele Cortese, Jae Il Shin, Christoph U. Correll, Marco Solmi
Summary: People with mood disorders are at increased risk of comorbid medical diseases. Interventions such as psychological therapies, exercise, and certain medications can improve physical health outcomes in mood disorders, but some medications may have negative effects. It is important to consider evidence from other disorders and individual RCTs when prioritizing effective treatments with beneficial or physically neutral profiles.
MOLECULAR PSYCHIATRY
(2023)
Article
Psychiatry
Marco Solmi, Markku Lahteenvuo, Christoph U. Correll, Antti Tanskanen, Jari Tiihonen, Heidi Taipale
Summary: Long-term use of prolactin-increasing antipsychotics is associated with an increased risk of low-energy fractures in people with schizophrenia, while prolactin-sparing antipsychotics show no significant association.
SCHIZOPHRENIA BULLETIN
(2023)
Review
Psychiatry
Samuele Cortese, Marco Solmi, Giorgia Michelini, Alessio Bellato, Christina Blanner, Andrea Canozzi, Luis Eudave, Luis C. Farhat, Mikkel Hojlund, Ole Kohler-Forsberg, Douglas Teixeira Leffa, Christopher Rohde, Gonzalo Salazar de Pablo, Giovanni Vita, Rikke Wesselhoeft, Joanna Martin, Sarah Baumeister, Natali S. Bozhilova, Christina O. Carlisi, Virginia Carter Leno, Dorothea L. Floris, Nathalie E. Holz, Eline J. Kraaijenvanger, Seda Sacu, Isabella Vainieri, Giovanni Ostuzzi, Corrado Barbui, Christoph U. Correll
Summary: Neurodevelopmental disorders such as ADHD, autism spectrum disorder, and intellectual disability can be identified early in development. However, there is a lack of valid and reliable biomarkers for the timely diagnosis of these disorders. A systematic review of studies on candidate diagnostic biomarkers for these disorders in children and adolescents found that none of the biomarkers met the criteria of specificity and sensitivity of at least 80% in two or more independent studies. Future research should focus on multivariable and multi-level approaches to identify valid candidate biomarkers.
Review
Clinical Neurology
Joshua T. Kantrowitz, Christoph U. Correll, Rakesh Jain, Andrew J. Cutler
Summary: Schizophrenia is a disabling disorder that has a significant impact on functioning and quality of life. Current antipsychotics have limitations in treating negative and cognitive symptoms and have troublesome side effects. There is a need for more effective and better-tolerated therapies.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
(2023)
Review
Clinical Neurology
Christoph U. Correll, Mikkel Hojlund, Christine Graham, Mark S. Todtenkopf, David McDonnell, Adam Simmons
Summary: This meta-analysis examines weight and metabolic effects during olanzapine treatment in patients with first-episode psychosis or early-phase schizophrenia. The results show that olanzapine is consistently associated with weight gain, especially in studies lasting more than 13 weeks. Metabolic changes observed suggest that randomized controlled trials may underestimate the metabolic sequelae compared to real-world treatment observations.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
(2023)
Article
Clinical Neurology
Junhee Lee, Christoph U. Correll, Tae Young Lee, Sanghoon Oh, Jayoun Kim, Sang Jin Rhee, Minah Kim, Se Hyun Kim, Yong Min Ahn, Kyooseob Ha, Jun Soo Kwon
Summary: This study aimed to validate a shorter version of the Bipolar Prodrome Symptom Interview and Scale (BPSS), the BPSS-Abbreviated Prospective (BPSS-AP), for use in clinical populations. Results showed that the BPSS-AP has good internal consistency, convergent validity, and discriminant validity, and can effectively identify individuals with bipolar disorder.
JOURNAL OF AFFECTIVE DISORDERS
(2023)
Review
Clinical Neurology
Gonzalo Salazar de Pablo, Anna Cabras, Joana Pereira, Henrique Castro Santos, Hector de Diego, Ana Catalan, Ana Gonzalez-Pinto, Boris Birmaher, Christoph U. Correll, Paolo Fusar-Poli
Summary: No systematic review has estimated the consistency and magnitude of the risk of developing bipolar disorder I-II in individuals at clinical high risk for bipolar disorder. This pre-registered systematic review included 13 studies reporting on nine prospective independent cohorts. The results show that the risk of developing bipolar disorder I/II ranges from 7.1% to 23.4% after 2 years, with higher risks for BD-I and BD-NOS subgroups.
JOURNAL OF AFFECTIVE DISORDERS
(2023)
Editorial Material
Psychology, Developmental
Samuele Cortese, Marco Solmi, Christoph U. Correll
JOURNAL OF CHILD PSYCHOLOGY AND PSYCHIATRY
(2023)
Article
Psychiatry
Anuradha Baminiwatta, Christoph U. Correll
Summary: This study provides a comprehensive scientometric review of the literature on tardive dyskinesia (TD) over more than five decades. The research output on TD peaked in the 1990s, gradually declined after 2004, and showed a small increase after 2015. The most prolific authors were Kane JM, Lieberman JA, and Jeste DV, and the most prolific journal was the Journal of Clinical Psychiatry.
FRONTIERS IN PSYCHIATRY
(2023)
Article
Psychiatry
Viktor B. Noehles, Felix Bermpohl, Peter Falkai, Christine Reif-Leonhard, Frank Jessen, Mazda Adli, Christian Otte, Andreas Meyer-Lindenberg, Michael Bauer, Kerstin Rubarth, Ion-George Anghelescu, Dan Rujescu, Christoph U. Correll
Summary: This study aims to investigate the patient characteristics, illness, and treatment characteristics of individuals with major depressive disorder (MDD) and suicidality. It focuses on the timing and factors associated with the offset, continuation, or reemergence of suicidality.
Article
Immunology
Ping-Tao Tseng, Bing-Syuan Zeng, Mein-Woei Suen, Yi-Cheng Wu, Christoph U. Correll, Bing-Yan Zeng, John S. Kuo, Yen-Wen Chen, Tien-Yu Chen, Yu-Kang Tu, Pao-Yen Lin, Andre F. Carvalho, Brendon Stubbs, Dian-Jeng Li, Chih-Sung Liang, Chih-Wei Hsu, Cheuk-Kwan Sun, Yu-Shian Cheng, Pin-Yang Yeh, Ming-Kung Wu, Yow-Ling Shiue, Kuan-Pin Su
Summary: This network meta-analysis suggests that high-dose EPA-dominant omega-3 PUFAs may have potential benefits in improving cognitive function in patients with Alzheimer's dementia. Omega-3 PUFAs have similar acceptability and safety profiles compared to placebo. Future large-scale RCTs should investigate different dosages of EPA-dominant omega-3 PUFAs in AD patients with varying levels of inflammation and psychopathology to further explore its therapeutic effects on cognitive decline.
BRAIN BEHAVIOR AND IMMUNITY
(2023)
Review
Psychiatry
Ole Kohler-Forsberg, Victoria Stiglbauer, Jelena Brasanac, Woo Ri Chae, Frederike Wagener, Kim Zimbalski, Oskar H. Jefsen, Shuyan Liu, Malik R. Seals, Stefanie Gamradt, Christoph U. Correll, Stefan M. Gold, Christian Otte
Summary: This umbrella systematic review and meta-analysis aimed to evaluate the efficacy and safety of antidepressant use in populations with medical diseases and comorbid depression. The results showed that antidepressants are effective and safe in treating and preventing depression in patients with comorbid medical disease.
Article
Pharmacology & Pharmacy
Michael Frey, Lukasz Smigielski, Elvira Tini, Stefanie Fekete, Christian Fleischhaker, Christoph Wewetzer, Andreas Karwautz, Christoph U. Correll, Manfred Gerlach, Regina Taurines, Paul L. Plener, Uwe Malzahn, Selina Kornbichler, Laura Weninger, Matthias Brockhaus, Su-Yin Reuter-Dang, Karl Reitzle, Hans Rock, Hartmut Imgart, Peter Heuschmann, Stefan Unterecker, Wolfgang Briegel, Tobias Banaschewski, Joerg M. Fegert, Tobias Hellenschmidt, Michael Kaess, Michael Koelch, Tobias Renner, Christian Rexroth, Susanne Walitza, Gerd Schulte-Koerne, Marcel Romanos, Karin Maria Egberts, Paolo Magni
Summary: This study investigated the relationship between drug dose and serum concentration of fluoxetine in children and adolescents and established the therapeutic serum reference range. The study found a positive correlation between dose and serum concentration of fluoxetine and its metabolite, with higher body weight and female sex associated with lower serum concentrations and therapeutic response. Most patients showed marked or minimal improvements during treatment, with no reported adverse effects.